Skip to main content
NVAX logo

NVAX · Novavax Inc

Track NVAX — free
$7.92 -0.05 (-0.57%)
Market Cap
$1.31B
Shares
165.01M
Volume · Nov 19 1.12M Avg daily vol (3M) 6.86M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.96 Open$7.90 Day$7.85–8.32 52W close$6.22–12.82 Avg vol 30d6.8M Short int46.3M · 28.1% of shares · 7.6d Short vol53% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 17
Investor event
Sanofi Milestone Pays $125 Million on COVID-Flu Combo Trial

Novavax earned a $125 million milestone from Sanofi after starting a Phase III combination COVID-flu vaccine trial in Europe. Sanofi also plans a U.S. trial, and Novavax is eligible to earn $225 million on a first U.S. sale.

3 source passages
We just earned, in the last month or so, a $125 million milestone from our ongoing partnership with Sanofi for their clinical initiation of a combination COVID flu vaccine with their world-leading flu vaccine and our differentiated COVID vaccine, non-mRNA protein-based. That trial started in Europe. And as a reminder for our audience, should they achieve a first sale of a combination vaccine with our COVID vaccine in the U.S., we would be eligible to earn a $225 million milestone and ongoing royalties for potentially decades after the launch of these products. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly net loss narrows sharply as research spending falls

Novavax reported revenue of $68.3 million and a net loss of $31.4 million, or $0.19 per share, for the three months ended September 30, 2026, versus a $202.4 million loss, or $1.25 per share, in 2025. R&D expenses fell to $52.4 million from $98.3 million.

Revenue $68.3M ▼ 3.0% Net loss $31.38M Diluted EPS -$0.19
Read from the MD&A section
4 source passages
Novavax tackles some of the world’s most significant health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. Revenue for the three months ended September 30, 2026 was $68.3 million as compared to $70.4 million for the same period in 2025, a decrease of $2.1 million. Net loss for the three months ended September 30, 2026 was $31.4 million, or $0.19 per share, basic and diluted, as compared to a net loss of $202.4 million, or $1.25 per share, basic and diluted, for the same period in 2025. Research and development expenses were $52.4 million for the three months ended September 30, 2026 as compared to $98.3 million for the three months ended September 30, 2025, a decrease of $45.8 million. Open the document at this passage
Nov 5
Current report 8-K
2026 revenue outlook raised after Sanofi milestone

Novavax raised its 2026 adjusted total revenue guidance to $385 - $415 million after earning a $125 million milestone from Sanofi, while third-quarter revenue was $68 million and net loss was $31 million.

Financial results
6 source passages
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights •Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point •In October, Novavax earned a $125 million milestone upon Sanofi’s launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe Adjusted Total Revenue5 | $385 - $415 | $235 - $275 •Total revenue for the third quarter of 2026 was $68 million, a 3% decrease compared to $70 million in the same period in 2025. •Net loss for the third quarter of 2026 was $31 million, compared to a net loss of $202 million in the same period in 2025. Open the document at this passage
Oct 29
Current report 8-K
Sanofi trial dosing triggers $125 million milestone

Sanofi dosed the fifth patient on October 28, 2026 in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, triggering a $125 million milestone payment to Novavax expected by the first quarter of 2027.

Regulation FD disclosure, Other events
3 source passages
On October 28, 2026 Sanofi Pasteur Inc. (“Sanofi”) dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, utilizing the Company’s COVID-19 component. Dosing of the fifth patient has triggered a $125 million milestone payment from Sanofi under the Company’s Collaboration and License Agreement with Sanofi. The Company anticipates receipt of payment by the first quarter of 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$411.65M
Trailing 12 months
Net income (TTM)
−$76.73M
Trailing 12 months
Revenue growth YoY
-3.0%
Year over year
Operating margin
-21.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$330.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.6%
Year over year · more shares
Price change (1Y)
+21.2%
Trailing year
Short interest
28.1%
Latest settlement · 7.6 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. Novavax raised its 2026 adjusted total revenue framework to $235 million to $275 million and improved combined GAAP R&D and SG&A guidance by $10 million at midpoint. Second-quarter total revenue fell 76% to $57 million, and the company reported a net loss of $53 million.

Bullish
  • + Raised full-year 2026 adjusted total revenue framework to $235 million to $275 million.
  • + Product sales rose 76% year over year on higher Matrix-M adjuvant demand and sales to license partners.
  • + Sanofi's expected Phase 3 CIC trial initiation in the U.S. or EU would trigger a $125 million milestone to Novavax.
  • + Sanofi manufacturing technology transfer, expected mid-2027, would trigger a $75 million milestone to Novavax.
  • + Combined GAAP R&D and SG&A expense guidance improved by $10 million at midpoint.
  • + Non-GAAP R&D expenses, net of partner reimbursement, fell 34% year over year to $48 million.
Bearish
  • − Total revenue fell 76% year over year to $57 million in the second quarter.
  • − Net loss of $53 million in the second quarter, compared with net income of $107 million a year earlier.
  • − Sanofi revenue fell 82% year over year, to 36 from 199 ($ in millions).
  • − Licensing, royalties and other revenue fell 83% year over year, to 38 from 229 ($ in millions).
  • − Cash declined to $724 million at June 30, 2026 from $751 million at December 31, 2025.
  • − Possible non-cash fixed asset write-off of up to $35 million in 2027.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −15%
below
Price vs 50-day avg −24%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 26%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −28%
trailing
6-month return −27%
trailing
YTD return +18%
this year
Relative strength −24%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
28.08% of shares out · ▼ -2.2% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
266 holders — near 3-yr high, broad support
Squeeze score 71
high risk · 0–100
Fundamentals
Excellent
Revenue growth +65%
Y/Y
EPS growth +310%
Y/Y
Balance sheet $3.6M
net debt
Quant / Vol
risk profile
Very High
Volatility 74%
annualized · 1-yr
Max drawdown −38%
past year
ATR 9.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 1 of last 4
Latest guidance · from the 8-K filed Nov 5, 2026
Full Year 2026 (as of Nov 5 2026)
Combined R&D and SG&A Expenses Lowered $375M – $395M
May 6, 2026 $380M – $420M changed to Nov 5, 2026 $375M – $395M
Non-GAAP Combined R&D and SG&A Expenses Maintained $315M – $335M
May 6, 2026 $310M – $340M changed to Nov 5, 2026 $315M – $335M
Full Year 2026 (as of Nov 5, 2026)
Nuvaxovid Product Sales1 $40M – $50M
Adjusted Licensing, Royalties and Other Revenue4 $170M – $180M
Adjusted Total Revenue5 $385M – $415M
Previous outlook earlier release · from the 8-K filed Feb 26, 2026

Still-open targets the latest release did not restate under the same label.

Nuvaxovid Product Sales · Full Year 2026 $35M – $45M
Adjusted Supply Sales · Full Year 2026 $40M – $50M
Adjusted Licensing, Royalties and Other Revenue · Full Year 2026 $155M – $175M
Prior guidance period ended · from the 8-K filed Jan 12, 2026
Combined R&D and SG&A Expenses, Net of Partner Reimbursement · FY 2025 E $250M
Guided vs delivered · last 4 settled
Total Revenue Full Year 2024
guided $800M – $1B
$682.16M Miss −24.2%
Total Revenue First Quarter 2024
guided $100M
$93.86M Miss −6.1%
Total Revenue FY 2023
guided $900M – $1.1B
$983.71M In line
Total revenue full year 2022
guided $2B
$1.98B Miss −0.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−15% Bearish
Price vs 50-day avg
−24% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
26% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
28.08% of shares out · ▼ -2.2% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
266 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $8 · 26% Range high $13
vs 200-day avg -15% vs 50-day avg -24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, marketable securities and restricted cash (Cash) $627M as of September 30, 2026 —
Non-GAAP R&D expenses, net of partner reimbursement non-GAAP $48M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NVAX
Novavax Inc
this stock
$1.31B +18.5% +64.7% — 28.1%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
266
% held
72.8%
Net QoQ
+2.6M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
174
View
Short & Settlement
Short Interest Falling
Shares short
46.3M
Days to cover
7.6d
Change
-1.0M sh
View
Short Volume
Short vol %
53%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
35
Value
$385
As of
Oct 22, 2026
View
Off-Exchange
Off-exchange %
46.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Pat Roberts
Amount
$1.0K–$15.0K
Traded
Oct 13, 2020
View
Financials
Financials
Revenue (FY)
$1.1B
Net income (FY)
$440.3M
EPS diluted
$2.58
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
19

Novavax earned a $125 million milestone from Sanofi after starting a Phase III combination COVID-flu vaccine trial in Europe. Sanofi also plans a U.S. trial, and Novavax is eligible to earn $225 million on a first U.S. sale.

View
Proposed Sales
Value
$75.9K
Shares
10.0K
Filed
May 19, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Novavax to Participate in Jefferi…
Published
Nov 11, 2026
View

Performance

5D 20D 120D MTD YTD
NVAX -20.2% -27.7% -27.4% -21.0% +18.5%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -16.3% -22.2% -24.0% -17.7% +11.4%
Key facts CIK 1000694 CUSIP 670002401 13F (30d) 290 filings 249 filers Visit website Investor relations